Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Teva & Alvotech Launch US Adalimumab Biosimilar

May 20, 2024

On 20 May 2024, Teva and Alvotech announced that their interchangeable high concentration citrate-free adalimumab biosimilar Simlandi® (adalimumab-ryvk, AVT02) is now available in the US.  Simlandi® is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

Simlandi® was FDA approved in February 2024 as the first interchangeable, high-concentration, citrate-free biosimilar to Humira.  Alvotech reports that nearly 88% of adalimumab prescriptions in the US are for the high-concentration formulation.

In July 2023, Teva and Alvotech announced a $40 million expansion to their US biosimilar partnership.  The agreement involved milestone payments and shared profits from the commercialisation of the biosimilars.